<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03923634</url>
  </required_header>
  <id_info>
    <org_study_id>CPH-401-201364</org_study_id>
    <nct_id>NCT03923634</nct_id>
  </id_info>
  <brief_title>Princess® RICH for the Correction of Fine Lines</brief_title>
  <acronym>RICH</acronym>
  <official_title>A Prospective Open-label, Multicenter Study Evaluating Princess® RICH in Correction of Fine Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Croma-Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Croma-Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible subjects deemed by the treating physician to have sufficient severity to merit
      treatment of either their lateral canthal lines (LCL) or perioral rhytids (PR) or both will
      be treated with Princess® RICH at the Baseline visit and at week 3 and 6.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Anticipated">February 6, 2020</completion_date>
  <primary_completion_date type="Actual">April 29, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of Princess® RICH to correct fine lines on the face including lateral canthal lines (LCL) and perioral rhytids (PR)</measure>
    <time_frame>Week 8 compared to Baseline</time_frame>
    <description>Percentage of responders at week 8 Responder is defined as at least &quot;improved&quot; versus baseline in the fine lines of lateral canthal lines (LCL) and/or perioral rhytids (PR) assessed with the GAIS (Gloabel Aesthetic Improvement Scale)
Global aesthetic improvement can be rated as 'very much improved', 'much improved', 'improved', 'no change' or 'worse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of Princess® RICH to correct fine lines on the face including lateral canthal lines (LCL) and perioral rhytids (PR)</measure>
    <time_frame>Week 12 and 16 compared to Baseline</time_frame>
    <description>Percentage of responders at week 12 and 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability of Princess® RICH to improve skin hydration</measure>
    <time_frame>Week 3, 6, 8, 12 and 16 compared to Baseline</time_frame>
    <description>Change from baseline at weeks 3, 6, 8, 12 and 16 in skin hydration. Skin hydration is measured using a corneometer device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability of Princess® RICH to improve skin tone</measure>
    <time_frame>Week 3, 6, 8, 12 and 16 compared to Baseline</time_frame>
    <description>Changes from baseline at weeks 3, 6, 8, 12 and 16 in skin tone. Skin tone is measured using a cutometer device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability of Princess® RICH to improve skin elasticity</measure>
    <time_frame>Week 3, 6, 8, 12 and 16 compared to Baseline</time_frame>
    <description>Change from baseline at weeks 3, 6, 8, 12 and 16 in skin elasticity. Skin elasticity is measured using a cutometer device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction with treatment</measure>
    <time_frame>Week 8, 12 and 16</time_frame>
    <description>Subject satisfaction with treatment at weeks 8, 12 and 16. Satisfaction with the treatment will be graded using one of the following categories: &quot;Very unsatisfied&quot;, &quot;Unsatisfied&quot;, &quot;Neither unsatisfied nor satisfied&quot;, &quot;Satisfied&quot;, or &quot;Very satisfied&quot;.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ocurrence and frequency of adverse events</measure>
    <time_frame>Throughout the study (16 weeks)</time_frame>
    <description>Assessment of occurrence and frequency of adverse events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Lateral Canthal Lines</condition>
  <condition>Perioral Rhytids</condition>
  <arm_group>
    <arm_group_label>Princess® RICH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will be injected with Princess® RICH (this is an open-label study).
Princess® RICH is injected into the lateral canthal lines and/or perioral rhytids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Princess® RICH</intervention_name>
    <description>Princess® RICH is injected into lateral canthal lines and/or perioral rhytids</description>
    <arm_group_label>Princess® RICH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects deemed by the treating physician to have LCL and/or PR of sufficient baseline
             severity to merit treatment with Princess® RICH to be corrected

          -  A negative urine pregnancy test at Visit 1 and commitment to use an adequate method of
             birth control for the duration of the clinical investigation (for women of
             childbearing potential only.)

          -  Healthy skin in the facial area and free of diseases that could interfere in cutaneous
             aging evaluation

          -  Willingness to abstain from any aesthetic or surgical procedures in the treatment area
             for the duration of the clinical investigation

          -  Written signed and dated informed consent

        Exclusion Criteria:

          -  Tendency to hypertrophic scars, pigment disorders or keloid formation.

          -  History of autoimmune disease or receiving therapy for modification of immune response

          -  Hypersensitivity to hyaluronic acid or glycerol.

          -  Permanent fillers in the areas to be treated.

          -  Subjects who are pregnant or breast feeding.

          -  Subjects who are anticoagulated or with history of bleeding disorder.

          -  Daily treatment with platelet aggregation inhibitors unless previously cleared by
             their primary care physician.

          -  Cutaneous, inflammatory and/or infectious processes present at V0, recurrent herpes
             simplex or (pre) cancerous lesions in the areas to be treated

          -  Known Diabetes mellitus or uncontrolled systemic diseases in the assessment of the
             investigator.

          -  Laser therapy, chemical peeling, dermabrasion or botulin toxin treatment in the area
             to be treated within less than three months prior to and during the course of the
             study.

          -  Current participation in another clinical investigation

          -  Subjects whose participation in clinical trials is prohibited by the Austrian Medical
             Devices Act (e.g, persons with a legal custodian appointed due to mental disability,
             prisoners, soldiers and other members of the armed forces, civil servants)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monika Sulovsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yuvell</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daisy Kopera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Universität Graz- Klinikum für Dermatologie und Venerologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Rappl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MaRa-Medical Aesthetic Research Academy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MaRa-Medical Aesthetic Research Academy</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität-Klinikum für Dermatologie und Venerologie</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>YUVELL</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

